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Abstract
Background: The aim of this study was to determine the distribution of vancomycin and daptomycin MICs
among methicillin-resistant Staphylococcus aureus (MRSA) blood isolates, the prevalence of heterogeneous
vancomycin-intermediate S. aureus (hVISA) and the relationship between hVISA and vancomycin MIC values.
Methods: A total of 175 MRSA blood isolates were collected from seven university hospitals in Turkey. All isolates
were tested for susceptibility to vancomycin and daptomycin by reference broth microdilution (BMD) and by
standard Etest method. BMD test was performed according to CLSI guidelines and Etest was performed according
to the instructions of the manufacturer. All isolates were screened for the presence of the hVISA by using macro
Etest (MET) and population analysis profile-area under the curve (PAP-AUC) methods.
Results: The vancomycin MIC50, MIC90 and MIC ranges were 1, 2, and 0.5-2 μg/ml, respectively, by both of BMD
and Etest. The daptomycin MIC50, MIC90 and MIC ranges were 0.5, 1 and 0.125 -1 μg/ml by BMD and 0.25, 0.5 and
0.06-1 μg/ml by Etest, respectively. The vancomycin MIC for 40.6% (71/175) of the MRSA isolates tested was >1 μg/ml
by BMD. No vancomycin and daptomycin resistance was found among MRSA isolates. Percent agreement of Etest MICs
with BMD MICs within ±1 doubling dilution was 100% and 73.1% for vancomycin and daptomycin, respectively. The
prevalence of hVISA among MRSA blood isolates was 13.7% (24/175) by PAP-AUC method. MET identified only 14 of
the hVISA strains (sensitivity, 58.3%), and there were 12 strains identified as hVISA that were not subsequently confirmed
by PAP-AUC (specificity, 92.1%).
Conclusions: Agreement between BMD and Etest MICs is high both for vancomycin and daptomycin. Daptomycin was
found to be highly active against MRSA isolates including hVISA. A considerable number of isolates are determined as
hVISA among blood isolates. As it is impractical to use the reference method (PAP-AUC) for large numbers of isolates,
laboratory methods for rapid and accurate identification of hVISA need to be developed.
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Background
Increasing number of studies from different regions of
the world report reduced susceptibility to glycopeptides
among methicillin-resistant Staphylococcus aureus (MRSA)
[1,2]. There are several studies suggesting incidence of
heterogeneous vancomycin-intermediate S. aureus (hVISA)
parallels the increase of vancomycin minimum inhibitory
concentration (MIC) [3-7]. Although the clinical significance
of vancomycin-intermediate S. aureus (VISA) is well defined,
the clinical relevance of hVISA isolates still remains
controversial. Several recent studies suggest a relationship
between vancomycin treatment failure or a worse clinical
outcome and increasing vancomycin MICs [1,2]. Although
understanding the changes in glycopeptide susceptibility of
MRSA is essential, the vancomycin susceptibility patterns
of MRSA isolates in Turkey is still largely unknown. Only a
few studies have reported the prevalence of hVISA among
MRSA isolates obtained from Turkish hospitals. Therefore,
a retrospective analysis of 175 MRSA blood isolates,
collected from seven major medical centers was performed
in order to determine vancomycin and daptomycin suscep-
tibility patterns, the correlation between vancomycin and
daptomycin MICs obtained by broth microdilution (BMD)
and Etest, the prevalence of hVISA and VISA among
these isolates and the relationship between hVISA and
vancomycin MIC values.
Methods
Bacterial isolates and antimicrobial susceptibility testing
A total of 175 MRSA blood isolates were collected
from seven tertiary-care teaching university hospitals
(approximately 30 MRSA strains per centre) in Turkey,
which were isolated between 2009 and 2010. These isolates
were collected as part of standard patient care and no ethical
approval was required for their use. All isolates were
tested for susceptibility to vancomycin and daptomycin by
reference BMD and by standard Etest. Daptomycin
was supplied by Novartis-Turkey and vancomycin
analytical powder was commercially purchased (Sigma
Chemical Company, St. Louis, MO). MIC determinations
for vancomycin and daptomycin were performed according
to the Clinical and Laboratory Standards Institute (CLSI)
M07 –A8 [8]. Mueller–Hinton broth adjusted to contain
physiological levels of calcium (50 mg/L) was used when
testing daptomycin. Etest was performed according to
the manufacturer’s guidelines using vancomycin and
daptomycin Etest strips (bioMérieux, France). The Etest
MIC was rounded up to the next highest concentration of
BMD for comparison between the Etest and the CLSI
MIC value where needed. Reference strains of VISA
(Mu50, ATCC 700699), hVISA (Mu3, ATCC 700698), and
methicillin- and vancomycin-susceptible S.aureus (ATCC
29213) were included as control organisms for the
antimicrobial susceptibility tests and population analysis
profile-area under the curve (PAP-AUC) analysis. Vanco-
mycin and daptomycin MIC breakpoints proposed by
CLSI for BMD method were applied to and used for Etest
in order to determine the categorical agreement between
the two methods. For determining the percent agreement
between BMD and the standard Etest, discrepancies
between MIC values of no more than one dilution
(± 1 dilution) were calculated. For assessment of categorical
agreement, minor error was defined as susceptible (S) or
resistant (R) by one method and intermediate (I) by the
other. Major error was defined as R according to Etest and
S according to BMD, and very major error was defined as S
according to Etest and R according to BMD [9]. MIC50 and
MIC90 values were used as parameters for giving results of
BMD and Etest methods. The MIC50 and MIC90 represent
the MIC value at which ≥50% and ≥90% of the isolates in a
test population are inhibited, respectively.
Screening for hVISA
All isolates were screened for the presence of the hVISA
and VISA phenotype by macro Etest (MET) using a high
inoculum (2 McFarland) and PAP/AUC method [10].
The MET was performed as previously described [11].
Briefly, several colonies were picked and suspended in
normal saline to obtain a 2.0 McFarland density standard.
One hundred microliters of this suspension was evenly
spread onto a 90-mm brain heart infusion (BHI) agar plate
and allowed to dry. Vancomycin and teicoplanin Etest
strips (bioMérieux, France) were applied to the surface of
the BHI agar and the plates were incubated at 35°C for
48 h. The plates were then examined and the results were
recorded at 24 and 48 h. Zones were read at complete
inhibition carefully observing for visual hazy growth and
microcolonies. A strain was considered positive for hVISA
by MET if microcolonies were detected at ≥8 μg/ml for
both vancomycin and teicoplanin or at ≥12 μg/ml for teico-
planin alone. The results were independently interpreted by
two investigators.
PAP/AUC was determined according to the Wootton
et. al.’s method [10]. Briefly, colonies grown overnight
on Columbia agar containing 5% sheep blood were sus-
pended in saline to a density equivalent to a 0.5 McFarland
turbidity standard. Dilutions of 10-3 (105 cfu/ml) and
10-6 (102 cfu/ml) were prepared in saline and 50 μl of
bacterial suspensions were inoculated onto BHI agar plates
containing 0, 0.5, 1, 2, 2.5, 4 and 8 μg/ml vancomycin.
Plates were air dried and incubated for 48 h at 35°C.
After incubation at 35°C for 48 h, bacterial colony
counts (log10 numbers of CFU/ml) were plotted against
the vancomycin concentration (0 to 8 mg/l). The graph
obtained was used to calculate AUC. The AUC was calcu-
lated for each isolate and divided by the AUC value of the
reference strain Mu3. The isolates were identified as
hVISA or VISA if the ratio of the AUC of the test isolate
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to that of the reference strain was ≥0.9 and >1.3 respect-
ively. PAP was the definitive criterion for defining the
hVISA phenotype. The performance of MET for detecting
hVISA was compared with the PAP-AUC ratio results.
Statistical analyses
Statistical Package for Social Sciences (SPSS) software
was used to analyze the correlation between vancomycin
and daptomycin MIC values with the Spearman correlation
test.
Results
A summary of MIC range, MIC50, MIC90 and the cumula-
tive vancomycin and daptomycin MIC distributions for
MRSA isolates determined by BMD and Etest methods
are presented in Table 1.
The MICs of vancomycin by microdilution were ≤1 μg/ml
for 104 (59.4%) isolates and 2 μg/ml for 71 (40.6%) isolates.
The distribution of vancomycin MICs among isolates
as determined by Etest was given in Table 1. When
rounded to the nearest doubling dilution, the overall fre-
quency of MRSA isolates for which the MIC was ≥2 μg/ml
was 17.1% (30/175) by Etest.
The overall essential agreement within ± 1 doubling
dilution between standard BMD method and Etest method
was 100% for vancomycin and 73.1% for daptomycin. No
correlation was observed between vancomycin MICs and
daptomycin MICs with BMD (r = 0.127, p = 0.095) and
Etest (r = 0.119, p = 0.117).
No VRSA or VISA isolates were detected among the
isolates tested. The overall rate of hVISA among MRSA
blood isolates was 13.7% (24/175). Using the MET, 26/175
(14.9%) isolates met the criteria for hVISA. The MET
identified only 14 of the hVISA strains (sensitivity, 58.3%),
and there were 12 strains identified as hVISA unconfirmed
by PAP-AUC (specificity, 92.1%) (Table 2).
The frequency of hVISA was MIC dependent irrespective
of the method used. The percentage of MRSA isolates that
are hVISA increased as the vancomycin MIC increases. Of
the 71 isolates with a vancomycin MIC of 2 μg/ml, 16
(22.5%) had the hVISA phenotype, whereas only 8 (7.8%)
of the 103 MRSA isolates with a vancomycin MIC of
1 μg/ml were hVISA strains by BMD method. Similarly by
Etest, 33.3% (10/30) of the isolates with vancomycin
MIC>1 μg/ml showed heteroresistance which was higher
than that of the vancomycin MIC≤1 μg/ml (9.7% [14/145])
(Table 3).
Discussion
Within the susceptibility range (≤2 μg/ml), several studies
report vancomycin MIC increases among MRSA over
time (MIC creep) [4,12-14]. Others could not detect such
a shift and attribute this phenomenon to the methods
used to analyze the data [3,15,16]. Meanwhile, isolates with
heteroresistance (hVISA) are emerging and the clinical
importance of such isolates is uncertain. Vancomycin
treatment failures were reported in patients infected with
susceptible isolates with MIC values of 1.5 to 2 μg/ml
[1,2,17]. Besides, the presence of VISA and hVISA has
been associated with worse clinical outcomes [18-20].
The frequency of MRSA isolates with vancomycin
MICs above a certain value such as >1 μg/ml vary widely
among studies and may depend on the method used
[1,2,21,22]. Our results show the vancomycin MIC for
40.6% of the MRSA strains tested was >1 μg/ml by BMD
and 17.1% by Etest. We cannot indicate a MIC creep
since an earlier data from the same centers are not avail-
able for comparison. The reason for relatively high
vancomycin MICs is not clear and may be clonal as
suggested by other studies in different settings [13,16].
PAP-AUC method is considered as the gold standard for
identifying hVISA. As this approach is time-consuming,
labor-intensive, expensive and unsuitable for routine
laboratories; multiple screening and detection methods have
been investigated for detection of hVISA [7,10,11,20,23,24].
In 2001, Walsh et al. [24] described the MET which detect
Table 1 The MIC range, MIC50, MIC90 and the cumulative vancomycin and daptomycin MIC distributions for MRSA
isolates determined by BMD and Etest methods
Drug-Method Cumulative % of isolates with the following MIC (μg/ml): MIC50 MIC90 MIC
range0.06 0.094 0.125 0.19 0.25 0.38 0.5 0.75 1 1.5 2
Vancomycin-BMD1 (n) 1 103 71 1 2 0.5-2
(%) 0.6 59.4 100
Vancomycin-Etest (n) 2 13 44 86 28 2 1 2 0.5-2
(%) 1.1 8.6 33.7 82.9 98.9 100
Daptomycin-BMD (n) 2 15 97 61 0.5 1 0.125-1
(%) 1.1 9.7 65.1 100
Daptomycin-Etest (n) 1 12 17 31 49 45 14 6 0.25 0.5 0.06-1
(%) 0.6 7.43 17.1 34.9 62.9 88.6 96.6 100
1BMD: Broth microdilution.
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isolates showing reduced susceptibility to glycopeptides.
This method was found superior to other methods and
exhibited good sensitivity and specificity compared to
PAP-AUC method and has been used for screening or as
the definitive test to determine the prevalence of hVISA
[6,20,24,25].
In this study, we could not find any VISA, while the
prevalence of hVISA was detected as 13.7% (24/175)
among MRSA blood isolates by PAP-AUC analysis. The
reported worldwide prevalence rates of hVISA differ
from 0% to 74% among countries [5,20,26,27]. Even in
the same country, there have been conflicting results
concerning the prevalence of hVISA. Some of these dispar-
ities in frequency could be due to differences in detection
methods used in the studies, the study designs and
patient populations tested [7,20,27]. In addition, in many
studies, the prevalence of hVISA wasn’t confirmed by
the PAP-AUC method. Therefore, it is very difficult to
compare the results of these studies with ours.
When the results of MET were evaluated, we demon-
strated that MET identified only 14 of the hVISA strains
(sensitivity, 58.3%), and 12 strains which were characterized
as hVISA were not subsequently confirmed by PAP-AUC
(specificity, 92.1%). Although the results of initial studies
showed that the MET had exhibited high sensitivity and
specificity compared with PAP-AUC method, [6,20,24,25]
the accuracy of this method varies significantly between
different studies [3,7,11,23,24,28]. The clinical significance
of isolates which are found as positive by MET but not by
PAP-AUC method is unknown. The cause of this discrep-
ancy could be due to the characteristics of the strains or
the criteria applied to define hVISA. Another reason for the
different sensitivity and specificity values might be the
different inoculum size (50 μl, 100 μl, 200 μl or 250 μl) used
in different studies [11,20,24,28-30]. Wootton et al.,
reported the sensitivity and specificity of MET as 76%
and 89% when they use 100 μl inoculum volume and
96 and 97% when the inoculum size was 200 μl, respect-
ively [11,24]. In current study we followed the manufactur-
er's recommended method and used 100 μl inoculum size
and found low sensitivity, similar to results reported by
some of the studies [3,11,23].
Previous studies have reported that the proportion of
hVISA isolates increased as the vancomycin MIC increased
[3-7]. Similar to these studies, the percentage of hVISA was
higher in the isolates with vancomycin MIC >1 μg/ml than
those with vancomycin MIC ≤1 μg/ml irrespective of the
testing methods we used.
Conclusions
This is the first study in Turkey investigating the prevalence
of hVISA isolates throughout the country, which were
collected from 7 centers. We have demonstrated that
the prevalence of hVISA among MRSA isolates recovered
from blood cultures in Turkey is high. The hVISA isolates
are more common among MRSA isolates with MICs
between 1 and 2 μg/ml. Therefore, it is essential to monitor
the effectiveness of vancomycin treatment especially when
the vancomycin MIC of the isolate is >1 μg/ml.
Because of the ability of screening methods for detection
of the hVISA isolates vary significantly, the frequency and
the clinical significance of the hVISA phenotype still
remains unclear. To date no standardized technique for
identifying hVISA phenotype has been established. Though
the PAP-AUC method is still considered to be the reference
method, it is not practical to measure PAP-AUC ratios for
large numbers of isolates, which limits its use in clinical
microbiology laboratories. Therefore, it is necessary to
develop improved laboratory screening methods for
rapid and accurate identification of hVISA.
Etest based methods are suggested as alternative methods
for detection of hVISA phenotype as these methods are
suitable for using in clinical microbiology laboratories. For
that purpose we used MET as a second method, but in our
evaluation, this method showed low sensitivity (58.3%) but
good specificity (92.1%) similar to recent studies. The
reevaluation of currently recommended MET cutoff
criteria might be useful for the detection of hVISA
isolates in the future. Finally, consistent with many studies,
all MRSA isolates including hVISA were found susceptible
Table 2 Comparison of macro Etest method (MET) to
population analysis profile-area under the curve (PAP-AUC)





n % n % n %
+ 14 8 12 6.9 26 14.9
- 10 5.7 139 79.4 149 85.1
Total 24 13.7 151 86.3 175 100
Table 3 Number and percentage of hVISA isolates at each
vancomycin MIC level among MRSA blood isolates
Vanco BMD MIC (μg/ml) Number of MRSA Percentage of hVISA
among MRSA n (%)
0,5 1 0
1 103 8 (7.8%)
2 71 16 (22.5%)
Vanco Etest MIC (μg/ml)
0,38 2 0
0,5 13 0
0,75 44 3 (%6.8)
1 86 11 (%12.8)
1,5 28 8 (%28,6)
2 2 2 (%100)
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to daptomycin both by BMD and Etest method. In recent
years there were reports which show an association
between increasing vancomycin MICs and daptomycin
non-susceptibility [30]. We did not observe higher
daptomycin MICs among isolates with higher vancomycin
MIC values. Therefore, daptomycin could be considered as
an alternative agent for the treatment of hVISA-infected
patients. Even if non-susceptibility to daptomycin is very
rare among MRSA isolates, further surveillance studies are
needed detect resistance to this agent in the future.
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